Ownership and insider activity for Anbio Biotechnology Class A Ordinary Shares (NNNN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B).
Price
| Price | $5.58 |
| Market Cap | $245M |
| Exchange | NASDAQ |
| Country | DE |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.2M | $7.1M | $9.7M | $11.8M | $7.8M |
| Short-term Investments | 0 | $1.6M | 0 | 0 | $4.1M |
| Receivables | $717500 | $3581 | $1.9M | $1.1M | $3.7M |
| Inventory | 0 | $353872 | 0 | 0 | 0 |
| Total Current Assets | $4.9M | $13.9M | $15.7M | $18.5M | $30.2M |
| Property, Plant & Equipment | 0 | $12059 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $4.9M | $14.0M | $15.8M | $18.9M | $30.2M |
| Accounts Payable | $1.9M | $1.4M | $827151 | $1.6M | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.4M | $1.4M | $993060 | $1.7M | $87836 |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.4M | $1.4M | $993060 | $1.7M | $87836 |
| Retained Earnings | $2.5M | $12.5M | $14.8M | $17.2M | $23.6M |
| Total Equity | $2.5M | $12.5M | $14.8M | $17.2M | $30.2M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$4.2M | -$8.7M | -$9.7M | -$11.8M | -$11.9M |
| Working Capital | $2.5M | $12.5M | $14.8M | $16.8M | $30.2M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 344.31 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 9018.70 |
Profitability
| Return on Equity | 27.49% |
| Return on Invested Capital | 25.46% |
| Return on Assets | 28.07% |
| Gross Margin | 86.10% |
| Operating Margin | 65.20% |
| Net Margin | 72.09% |
Related companies: ANGO · AVNS · CLPT · CMPS · CYH · GOSS · KALV
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of NNNN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks